The Rate of Visual Loss in Behcet's Disease

Mamo, Jubran G.

doi:10.1001/archopht.1970.00990040453009

Cited by 128 publications

(50 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In keeping with previous studies (7,44 -47), most of our patients developed eye disease at onset or within the first few years from disease onset. Contrary to the poor prognosis for eye involvement reported by older studies (44,45,(47)(48)(49), we observed an overall favorable prognosis, in agreement with more recent studies (46,50 -52). Only 1 (11%) of 9 patients with posterior eye involvement had loss of useful vision in at least 1 eye at the end of the followup, whereas almost all patients had improvement of visual acuity once treatment was started.…”

Section: Seventeen-year Study Of Behçet's Disease In Italysupporting

confidence: 90%

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

Salvarani¹,

Pipitone²,

Catanoso³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate the epidemiology and clinical course of Behçet's disease (BD) over a 17-year period in a defined area of northern Italy. Methods. All patients with incident BD diagnosed over a 17-year period (from January 1, 1988 to December 31, 2004) living in the Reggio Emilia area were identified through the following sources: physicians at Reggio Emilia Hospital, medical practitioners, and community-based specialists. We identified all patients registered in a centralized index and in the Reggio Emilia district database for rare diseases. Patients were followed up from the time of diagnosis until either their death or April 1, 2005. Results. Eighteen patients (9 men and 9 women) had complete BD. Mean ؎ SD age at diagnosis was 33 ؎ 7 years. The incidence rate of BD was 0.24 per 100,000. The prevalence of BD on January 1, 2005 was 3.8 per 100,000. No patients died during the followup period. Although all patients developed oral ulceration during the disease course, 22.2% had no oral lesions at disease onset. Eye disease occurred in 55.6%. Ocular disease was more common in men and appeared at disease onset or within the first few years of disease onset (median 3 years). Only 1 patient had loss of useful vision in at least 1 eye at the end of followup. In all affected patients, visual acuity improved once treatment was started. Conclusion. This population-based study is the first to report the prevalence and incidence of BD in Italy. In Italian patients, BD is nonfatal and the prognosis of eye disease is good.

show abstract

Section: Seventeen-year Study Of Behçet's Disease In Italysupporting

confidence: 90%

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

Salvarani¹,

Pipitone²,

Catanoso³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Repeated attacks of uveitis can cause blindness [1][2][3]. Involvement of the gastrointestinal tract, central nervous system, and large vessels is less frequent, although it can be life threatening [1,2,[4][5][6].…”

Section: Introductionmentioning

confidence: 99%

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

Giardina

Ferrante²,

Ciccia³

et al. 2009

Rheumatol Int

View full text Add to dashboard Cite

The aim of the study was to assess the long-term eYcacy and safety of InXiximab therapy in the treatment of patients with Behçet's disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg InXiximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg InXiximab every 8 weeks. At each visit data on clinical symptoms, response to therapy and adverse events were collected. The primary outcome of interest was to assess the clinical eYcacy (total or partial recovery) of inXiximab. Secondary end points were to evaluate quality of life and to monitor the safety of the drug. Eighteen patients achieved a total remission. Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy. InXiximab was well tolerated throughout the study. A case of non-Hodgkin lymphoma was observed within 6 months.Minor side eVects were headache, dizziness, tachycardia that regressed spontaneously and did not entail interruption. Anti-nuclear antibodies were not detected during the period of observation.

show abstract

“…The most dreaded potential side effects of chlorambucil are a dosagerelated increase in the risk of malignancy and bone marrow aplasia (9,(20)(21) . In earlier reports on chlorambucil (7)(8)18) , treatment duration varied from 3 to 17 months, dosage varied from 5 to 24 mg/day with a follow-up no longer than 6 years. The cumulative dose ranged from 1710 to 2250 mg (18) .…”

Section: Discussionmentioning

confidence: 99%

“…In the past, blindness was observed in 90% of untreated patients followed up for a mean period of 3.6 years (7) and in as many as 74% of the eyes during the first 6 to 10 years after the onset of the ocular symptoms, regardless of the type of treatment (27) . More recent investigations show a downward trend in the prevalence of blindness among patients with ocular involvement due to Behçet's disease (4)(5)(6) , attributed to the use of immunosuppressants.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

Zaghetto¹,

Yamamoto²,

Souza³

et al. 2010

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

The Rate of Visual Loss in Behcet's Disease

Cited by 128 publications

References 1 publication

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

Contact Info

Product

Resources

About